0KHE Stock Chart & Stats
$128.26
-$2.42(-2.17%)
At close: 4:00 PM EDT
$128.26
-$2.42(-2.17%)
Day’s Range― - ―
52-Week Range$80.00 - $169.27
Previous CloseN/A
Volume7.00
Average Volume (3M)981.00
Market Cap
$18.45B
Enterprise Value$15.02B
Total Cash (Recent Filing)$1.02B
Total Debt (Recent Filing)$3.34B
Price to Earnings (P/E)78.7
Beta0.85
Next Earnings
Nov 03, 2026EPS Estimate
1.3Next Dividend Ex-DateN/A
Dividend Yield0.17%
Share Statistics
EPS (TTM)2.10
Shares Outstanding111,586,400
10 Day Avg. Volume1,553
30 Day Avg. Volume981
Financial Highlights & Ratios
PEG Ratio-3.41
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue5.16
Enterprise Value/Gross Profit9.90
Enterprise Value/Ebitda19.58
Forecast
1Y Price Target
$141.75Price Target Upside10.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)5.36
Revenue Forecast (FY)$2.85B
Bulls Say, Bears Say
Bulls Say
Diagnostics GrowthDiagnostics is showing broad-based momentum, with reproductive health growing at a mid-teens rate and immunodiagnostics also accelerating outside China. This growth supports a stronger business mix and can provide durable demand across recurring testing and laboratory workflows.
Cash Generation And DeleveragingStrong free cash flow and 117% adjusted net-income conversion give Revvity internal funding for investment, debt reduction, and shareholder priorities. Retiring debt and targeting lower leverage should improve financial flexibility and reduce balance-sheet constraints over the coming quarters.
High-Content Screening DemandDouble-digit order growth and a multi-year-high backlog indicate improving demand for Revvity’s high-content screening platforms. A larger installed base can support future instrument revenue while also creating opportunities for related consumables, software, and service purchases.
Bears Say
Software Revenue VolatilityThe sharp Signals decline shows that software revenue remains exposed to contract timing and comparison effects, making near-term growth less predictable. Although management expects recovery in the second half, choppy recognition can complicate planning and weaken the consistency of the software contribution.
Margin Compression And Earnings VolatilityCurrent profitability is solid but remains below Revvity’s stronger prior-cycle levels, while the historical loss demonstrates earnings volatility. Margin recovery is therefore important for durable shareholder returns, because weaker operating profitability reduces the cushion available against demand or execution pressures.
China Immunodiagnostics ChallengesThe planned divestiture reflects structural difficulty in China immunodiagnostics and will change Revvity’s geographic and business mix. Until closing, the business remains in reported results, while the transition may require continued execution and could reduce exposure to a previously contributing operation.
Revvity News
0KHE FAQ
What was Revvity’s price range in the past 12 months?
Revvity lowest share price was $80.00 and its highest was $169.27 in the past 12 months.
What is Revvity’s market cap?
Revvity’s market cap is $18.45B.
When is Revvity’s upcoming earnings report date?
Revvity’s upcoming earnings report date is Nov 03, 2026 which is in 5 days.
How were Revvity’s earnings last quarter?
Revvity released its earnings results on Aug 04, 2026. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.214 by $0.196.
Is Revvity overvalued?
According to Wall Street analysts Revvity’s price is currently Undervalued.
Does Revvity pay dividends?
Revvity pays a Quarterly dividend of $0.07 which represents an annual dividend yield of 0.17%. See more information on Revvity dividends here
What is Revvity’s EPS estimate?
Revvity’s EPS estimate is 1.3.
How many shares outstanding does Revvity have?
Revvity has 111,586,400 shares outstanding.
What happened to Revvity’s price movement after its last earnings report?
Revvity reported an EPS of $1.41 in its last earnings report, beating expectations of $1.214. Following the earnings report the stock price went down -3.071%.
Which hedge fund is a major shareholder of Revvity?
Currently, no hedge funds are holding shares in GB:0KHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revvity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$141.75 (10.52% Upside)
$141.75 (10.52% Upside)
Blogger Sentiment
Neutral
GB:0KHE Sentiment 78%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.83%
12-Months-Change
Fundamentals
Return on Equity
3.27%
Trailing 12-Months
Asset Growth
-2.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Revvity
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
0KHE Company Deck
0KHE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally positive operational and financial picture: revenue and EPS beat with upgraded full-year guidance, strong Diagnostics performance, accelerating high-content instrument orders and robust cash flow and balance sheet improvements. Key near-term weaknesses include a sizable decline in Signals software revenue this quarter, some production/timing constraints that shifted instrument revenue into Q3, and portions of the quarter's outperformance tied to one-time tariff refunds and tax timing. Management plans reinvestments of a portion of one-time benefits while highlighting new software capabilities and AI-driven demand as multi-year growth drivers—though the AI opportunity is still early and not fully quantifiable.View all GB:0KHE earnings summaries0KHE Revenue Breakdown
50.11% Life sciences
49.89% Diagnostics
0KHE Stock 12 Month Forecast
Average Price Target
$141.75
▲(10.52% Upside)